News headlines about Jazz Pharmaceuticals (NASDAQ:JAZZ) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Jazz Pharmaceuticals earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 45.3242920455632 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the headlines that may have effected Accern’s scoring:
- Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : December 12, 2017 (finance.yahoo.com)
- Kenmare Capital Partners Has Upped By $1.21 Million Its Facebook (FB) Holding; Jazz Pharmaceuticals PLC (JAZZ)’s … – Hill Country Times (hillcountrytimes.com)
- Brokerages Anticipate Jazz Pharmaceuticals PLC (JAZZ) Will Post Quarterly Sales of $441.37 Million (americanbankingnews.com)
- B. Riley Reaffirms Buy Rating for Jazz Pharmaceuticals (JAZZ) (americanbankingnews.com)
- Jazz Pharmaceuticals’ (JAZZ) “Buy” Rating Reiterated at Cantor Fitzgerald (americanbankingnews.com)
JAZZ has been the topic of a number of recent research reports. FBR & Co initiated coverage on Jazz Pharmaceuticals in a research note on Thursday, October 19th. They issued a “buy” rating and a $206.00 target price on the stock. Royal Bank of Canada lowered their target price on Jazz Pharmaceuticals from $210.00 to $195.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 8th. Cantor Fitzgerald restated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 29th. Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a research note on Thursday, September 28th. They issued a “neutral” rating and a $165.00 target price on the stock. Finally, UBS restated a “buy” rating and issued a $172.00 target price (down previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Monday, September 25th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $181.28.
In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $150.00, for a total transaction of $150,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Iain Mcgill sold 8,000 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $133.42, for a total value of $1,067,360.00. Following the transaction, the senior vice president now directly owns 28,383 shares of the company’s stock, valued at approximately $3,786,859.86. The disclosure for this sale can be found here. Insiders have sold 9,352 shares of company stock worth $1,264,243 in the last quarter. 4.30% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Jazz Pharmaceuticals (JAZZ) Receives Daily News Impact Score of 0.24” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/12/12/jazz-pharmaceuticals-jazz-receives-daily-news-impact-score-of-0-24.html.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.